|US Brand||Generic Sovaldi|
|IN Brand||Hepcinat | Sovihep | MyHep | Sofovir|
|Manufacturing by||Natco | Zydus | Mylan | Hetero|
|Form release||bottle of 28 tablets|
|Estimated shipping time||7 – 18 days (Depending from the Country)|
|Availability, Prices & Order||through request form|
It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, or daclatasvir.
Sofosbuvir is a new drug candidate for hepatitis C treatment, with the chemical name L-Alanine, N-[[P(S),2′R]-2′-deoxy-2′-fluoro-2′-methyl-P-phenyl-5′-uridylyl]-, 1-methylethyl ester and a molecular formula of C22H29FN3O9P. Previously known as PS-7977 or GS-7977, it has shown promising results in numerous in vitro studies against all the genotypes of HCV. It is a nucleotide analog that is a highly potent inhibitor of the NS5B polymerase in HCV. This drug has shown high efficacy in combination with several other drugs with and without PEG-INF, against HCV. Sofosbuvir is of special interest among the directly acting antiviral drugs under development, due to its high potency, low side effects, oral administration, and high barrier to resistance.
The efficacy and safety of sofosbuvir in patients with different HCV genotypes and with various combinations of drugs have been tested in numerous clinical trials. A dose of 400 mg of sofosbuvir has been found to be most effective, with treatment durations ranging from 12 to 24 weeks, in various combinations of PEG-IFN and ribavirin in phase 2 clinical trials. The NEUTRINO study found SVR to be 90% (95% CI, 87 to 93) 12 weeks after therapy with sofosbuvir + PEG-INF + ribavirin; this was found to be superior to the adjusted historical response rate of 60% (P < 0.001). Similar positive results have been found in numerous phase 3 clinical trials. Furthermore, recent phase 1 and 2 studies of sofosbuvir in combination with other DAAs have also shown promising results >more info>
Sofosbuvir has shown a good safety profile in clinical trials; a small decrease in the Hb levels (0.54 mg/dl) and reduction in the cumulative events in comparison to interferon-containing regimens is seen. Common adverse events observed include: Headache, insomnia, fatigue, nausea, dizziness, pruritis, upper respiratory tract infections, rash, back pain, grade 1 anemia, and grade 4 lymphopenia. No neutropenia, thrombocytopenia, or any serious adverse events are associated with sofosbuvir treatment. In the monotherapy treatment groups, nausea and fatigue seemed to be the only adverse events possibly correlated to sofosbuvir.